This has been an exciting year for medical office technology. Improvements in otoscopy, hemoglobin analyzers, tissue adhesives, and topical skin preps top the list of innovations.
Roflumilast cream 0.15% reduces itch for atopic dermatitis patients 6 years and older
In identical phase 3 trials, roflumilast demonstrated topline positive results, reducing itch in children and adults with mild to moderate AD.
Recognize & Refer: Hemangiomas in pediatrics
Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.
Lebrikizumab demonstrates strong phase 3 data for atopic dermatitis
A recent study indicated that lebrikizumab treatment for 16 weeks was effective for adolescents and adults with moderate-to-severe atopic dermatitis.
Tapinarof cream safe, effective for pediatric atopic dermatitis
Results from a recent phase 3 clinical trial demonstrated topline safety and efficacy results for tapinarof cream, 1% (VTAMA; Dermavant) as a potential treatment for atopic dermatitis in patients 2 years and older.
FDA accepts NDA for berdazimer gel to treat molluscum contagiosum
Following positive results from a phase 3 clinical trial, the FDA has accepted a New Drug Application for berdazimer gel, 10.3% (Novan) for treating patients with molluscum contagiosum.
Dupilumab sNDA accepted for chronic spontaneous urticaria in adolescents
A supplemental Biologics License Application has been accepted by the FDA for treating adolescents and adults with chronic spontaneous urticaria.
2 Clarke Drive Cranbury, NJ 08512